Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN.
Screening for cervical cancer is often considered the success story for cancer screening in the United States. However, much room for improvement still exists. For example, experts have yet to establish the best follow-up strategy for women with an abnormal Papanicolaou test and high-risk human papillomavirus (HPV) followed by a normal colposcopy or biopsy that is negative for cervical intraepithelial neoplasia. The incorporation of HPV testing has allowed the development of a more sensitive and cost-efficient strategy. This article presents a brief overview of related guidelines and current modalities, and reviews selected studies. Finally, future directions and a possible schema for clinical management of these patients are included.
Kimball
Kristopher J
KJ
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, 618 South 19th Street, OHB 538, Birmingham, Alabama 35249, USA. kimballkj@gmail.com
Huh
Warner K
WK
D004279:DNA, Viral / Q000032:analysis; D003663:Decision Trees; D005260:Female; D006801:Humans; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000473:pathology / Q000517:prevention & control*; D014626:Vaginal Smears; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000517:prevention & control*
D004279:DNA, Viral